Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

C-MER Medical Holdings Limited
希瑪醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

VOLUNTARY ANNOUNCEMENT
ACQUISITION OF AN ENDOSCOPY CENTRE

This announcement is made by C-MER Medical Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

ACQUISITION OF AN ENDOSCOPY CENTRE

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on 26 August 2025, C-MER Eye Care Medical Group Limited (希瑪眼科醫療集團有限公司), a subsidiary of the Company, entered into a sale and purchase agreement with three individual sellers to acquire 58% of the entire issued capital of Hong Kong Endoscopic Diagnosis and Therapy Centre Limited (香港內視鏡檢驗及治療中心有限公司), trading as "Hong Kong Endoscopy Centre" ("**Hong Kong Endoscopy Centre**") (the "**Acquisition**"). Hong Kong Endoscopy Centre will become a subsidiary of the Company upon completion of the Acquisition, which is expected to be in or around October 2025.

REASONS FOR AND BENEFITS OF THE ACQUISITION

Hong Kong Endoscopy Centre was established in 2016 and is located in Grand Plaza, Mongkok, Hong Kong with three endoscopy rooms. The specialist medical services provided mainly included gastroscopy, colonoscopy and cystoscopy.

In meeting the demand for quality medical services, the Group has always been exploiting possible business opportunities. Headquartered in Hong Kong with nine years of operation history, Hong Kong Endoscopy Centre is a well-established endoscopy centre in Hong Kong. The Directors consider that Hong Kong Endoscopy Centre demonstrates strengths in management, quality medical services and financial performance, and this move will expand our medical service in Hong Kong, enable the Company to leverage our existing patient base to create synergy with our business in Hong Kong and our cross border business in Shenzhen. The Directors are of the view that the Acquisition is in the interests of the Company and its shareholders as a whole.

IMPLICATIONS UNDER THE LISTING RULES

To the best knowledge, information and belief of the Directors after having made all reasonable enquiries, as at the date of this announcement, the sellers of the Acquisition are third parties independent of the Company and its connected persons.

As all the applicable percentage ratios in respect of the Acquisition under Rule 14.07 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the "**Listing Rules**") are below 5%, the Acquisition does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules.

Shareholders and potential investors should be aware that the completion of the Acquisition is subject to certain conditions precedent. Therefore, shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
C-MER Medical Holdings Limited
Ms. LI Xiaoting
Vice Chairman, Executive Director and Chief Executive Officer

Hong Kong, 26 August 2025

As at the date of this announcement, the Board comprises its chairman and independent non-executive Director, Dr. Rex AUYEUNG Pak-kuen; two executive Directors, namely Ms. LI Xiaoting (Vice Chairman and Chief Executive Officer) and Dr. LEE Yau Wing Vincent; and five other independent non-executive Directors, namely Dr. KO Wing Man (Vice Chairman), Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen, Mr. YIN Ke and Mr. LI Ling Cheung Raymond.